# IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC

> **NCT04945421** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 30 (actual)

## Conditions studied

- NPC

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** IBI310

## Key facts

- **NCT ID:** NCT04945421
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-23
- **Primary completion:** 2022-04-25
- **Final completion:** 2023-02-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04945421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04945421, "IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT04945421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*